Loading
A phase 1/2 trial of Orellanine in renal cell carcinoma, run by Oncorena AB, now recruiting.
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT05287945 by Oncorena AB, with 75 participants planned, started 2023-08-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Orellanine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Papillary renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/